Denali’s DNL310 Eyes Accelerated FDA Approval With Encouraging Phase 1/2 Data in Hunter Syndrome

Published Date: 08 Sep 2024

Denali Therapeutics plans to seek accelerated FDA approval for DNL310 in Hunter syndrome, showing significant biomarker improvements and clinical benefits in ongoing trials.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.

2.

Reducing social media to an hour a day boosts young people's self-image.

3.

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

4.

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

5.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot